CHECKMATE PHARMACEUTICALS IN (CMPI) Stock Analyst Ratings
NASDAQ:CMPI - Nasdaq - US1628181083 - Common Stock
ChartMill assigns a Buy % Consensus number of 83% to CMPI. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 12.75. This target is 21.43% above the current price.
CMPI was analyzed by 8 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about CMPI.
In the previous month the buy percentage consensus was at a similar level.
CMPI was analyzed by 8 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2022-04-20 | BTIG | Downgrade | Buy -> Neutral |
| 2021-10-06 | B of A Securities | Upgrade | Neutral -> Buy |